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latelet Indexes in Relation to Target
rgan Damage in High-Risk Hypertensive Patients
Substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
unil K. Nadar, MRCP, Andrew D. Blann, PHD, Sridhar Kamath, MRCP,
. Gareth Beevers, MD, FRCP, Gregory Y. H. Lip, MD, FRCP
irmingham, United Kingdom
OBJECTIVES We sought to investigate the relationship between target organ damage (TOD) in hyper-
tension and a prothrombotic/hypercoagulable state, using a new technique of “platelet lysis”
to quantify the amount of P-selectin per platelet (pP-sel), and to correlate it with other
platelet markers (e.g., mass, volume and granularity, soluble P-selectin [sP-sel], and
beta-thromboglobulin [beta-TG]).
BACKGROUND The increased risk of TOD in hypertension may be related to a prothrombotic/
hypercoagulable state, with abnormalities in platelets, such as increased expression of
P-selectin.
METHODS We studied 199 patients (mean age 68 years, 75% men) with hypertension. Of these, 125 had
TOD (e.g., stroke, previous myocardial infarction, angina, left ventricular hypertrophy).
Values obtained were compared with those from 59 healthy normotensive control subjects
(mean age 68 years, 58% men).
RESULTS Hypertensive patients had a higher mean platelet volume, mass, pP-sel, sP-sel, and beta-TG
and lower platelet granularity (all p  0.01), but a similar platelet count, as compared with
controls. Within the hypertensive group, those with evidence of TOD had significantly larger
platelets with greater mass but had lower granularity, sP-sel, and pP-sel levels than those
without TOD, possibly reflecting increased aspirin use. On multivariate analysis, aspirin use
was a determinant of pP-sel (p  0.03) and sP-sel (p  0.01), but the use of other drugs or
other co-morbidity (e.g., diabetes, smoking) did not influence either P-selectin value.
CONCLUSIONS Patients with hypertension have evidence of changes in platelet physiology, as reflected by a
higher level of pP-sel. Patients with TOD also had larger platelets, with greater mass, and the
use of aspirin lowered pP-sel and sP-sel levels. These changes may have implications for the
pathophysiology of cardiovascular and cerebrovascular disease in hypertension. (J Am Coll
Cardiol 2004;44:415–22) © 2004 by the American College of Cardiology Foundationr
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aespite advances in the understanding of hypertension and
ts treatment, the precise mechanisms by which hyperten-
ion acts as a cardiovascular risk factor are not fully under-
tood. In recent years, it has become evident that markers of
oagulation (e.g., fibrinogen) are predictors of cardiovascu-
ar events. Many such abnormalities are present in hyper-
ensive patients, indicating that hypertension may confer a
rothrombotic or hypercoagulable state; indeed, despite the
lood vessels in hypertension being exposed to high pres-
ures, the complications of hypertension are paradoxically
hrombotic rather than hemorrhagic (1,2). In addition to
evere thrombotic events such as stroke and myocardial
nfarction (MI), patients with long-standing hypertension
lso show evidence of damage to other organs, such as left
entricular hypertrophy, collectively referred to as target
rgan damage (TOD).
From the Haemostasis Thrombosis and Vascular Biology Unit, University Depart-
ent of Medicine, City Hospital, Birmingham, United Kingdom. This study was
upported by the Peel Medical Research Trust and the City Hospital Research and
evelopment Program for the Haemostasis Thrombosis and Vascular Biology Unit.
Manuscript received February 8, 2004; revised manuscript received March 17,i004, accepted March 29, 2004.More recently, attention has been directed toward the
ole of platelets in the pathogenesis of the complications of
ypertension, and raised plasma P-selectin is an example of
his activity (3,4). P-selectin (CD62P), an adhesion mole-
ule facilitating the adhesion of platelets to leukocytes and
o the endothelium, is a component of the membrane of the
ndothelial Weibel-Palade body and the membrane of the
latelet alpha and dense granules. During activation and
dhesion, platelets mobilize their alpha granules so that
-selectin appears at the surface and is subsequently shed
nto the plasma (5). This shed P-selectin is measured as
oluble P-selectin (sP-sel), and it is now believed that most,
f not all, of this sP-sel in the plasma is of platelet origin
nd, to some extent, parallels levels of plasma beta-
hromboglobulin (beta-TG), a more established platelet
arker (6,7).
Plasma levels of sP-sel are becoming recognized as a
arker of platelet activation in various conditions, such as
schemic heart disease (8,9), atrial fibrillation (10,11), and
ypertension (12,13). However, the amount of P-selectin in
particular platelet (pP-sel) has not been extensively studiedn hypertension, because, until recently, the main method of
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Platelet and Soluble P-Selectin in Hypertension July 21, 2004:415–22stimating expression of P-selectin has been by flow cytom-
try (14) or whole platelet enzyme-linked immunosorbent
ssay (ELISA) (15). We have recently reported a novel
ethod of quantifying total pP-sel levels by lysing a set
umber of platelets with the detergent Triton X-100 and
easuring P-selectin by ELISA in the resultant lysate (16).
inally, advances in flow cytometry have enabled the devel-
pment of additional measures of platelet biology, not only
ean platelet volume (MPV), but also platelet mass and
omponent/granularity, and although the precise patho-
hysiologic implications of these three indexes is unclear,
hey may have a role in unstable angina and acute MI (17).
Due to the increased expression of surface membrane
-selectin by platelets on activation, we hypothesized that
he amount of pP-sel would be elevated in hypertensive
atients compared with healthy age- and gender-matched
ontrol subjects, and that this, in turn, would vary depend-
ng on the presence or absence of TOD. We also hypoth-
sized that other platelet indexes (e.g., platelet granularity,
ass, and volume) would differ between the various groups.
o test this hypothesis, we examined platelet samples from
atients with hypertension with and without TOD.
ETHODS
atients. The study was part of the Anglo-Scandinavian
ardiac Outcomes Trial (ASCOT), which compares hyper-
ensive regimens: overall rationale, methods, and inclusion
riteria have been previously described in detail (12,18).
riefly, the inclusion criteria were patients age 40 to 80
ears with either untreated hypertension (systolic blood
ressure [SBP] 160 mm Hg and/or diastolic blood pres-
ure [DBP] 100 mm Hg) or treated hypertension (SBP
140 mm Hg and/or DBP 90 mm Hg). In addition,
atients were required to have three or more of the follow-
ng risk factors: 1) left ventricular hypertrophy; 2) other
lectrocardiographic abnormalities; 3) diabetes; 4) history of
erebrovascular disease, including transient ischemic attack;
) male gender; 6) age 55 years; 7) microalbuminuria/
roteinuria; 8) smoking; 9) plasma total/high-density li-
oprotein cholesterol ratio 6; 10) history of a coronary
rtery disease event occurring in a first-degree relative before
Abbreviations and Acronyms
ASCOT  Anglo-Scandinavian Cardiac Outcomes Trial
beta-TG  beta-thromboglobulin
DBP  diastolic blood pressure
MI  myocardial infarction
MPG  mean platelet granularity
MPM  mean platelet mass
MPV  mean platelet volume
pP-sel  P-selectin per platelet
SBP  systolic blood pressure
sP-sel  soluble P-selectin
TOD  target organ damagehe age of 55 years in males or 60 years in females; or 11) ceripheral vascular disease, as per the Edinburgh claudica-
ion questionnaire (19). Patients were excluded if they had
history of malignant or secondary hypertension, congestive
ardiac failure, fasting serum triglycerides 4.5 mmol/l, or
ajor concomitant noncardiovascular disease or were taking
arfarin. Target organ damage was defined as a previous
ardiovascular event (stroke [cerebrovascular accident],
ransient ischemic attack, MI, left ventricular hypertrophy,
r renal failure [serum creatinine 140 mmol/l]). The
SCOT patients were recruited into this cross-sectional
tudy after stabilization on ASCOT trial drug therapy, all
fter being two or more years into the trial.
We also recruited 59 healthy normal subjects from the
ospital staff, relatives of the patients, or those attending the
ospital for routine cataract or hernia surgery. The subjects
ere not taking any regular medication and were nonsmok-
rs, with no clinical evidence of vascular, metabolic, neo-
lastic, or inflammatory disease by a careful history, exam-
nation, and routine laboratory tests. These subjects were
ormotensive (SBP/DBP 140/90 mm Hg) and in sinus
hythm.
aboratory. Blood was drawn from an antecubital with
traumatic venipuncture into vacutainers containing citrate,
heophylline, adenosine, and dipyridamole (CTAD) for
stimating beta-TG, as well as citrate for pP-sel and sP-sel.
he blood samples collected in the CTAD tubes were
mmediately placed on ice, and plasma was separated within
h of collection. Aliquots were stored at70°C to facilitate
atch analysis. Levels of beta-TG were determined by
LISA (Asserachrom, Diagnostica Stago, Asniere sur
eine, France). P-selectin in citrated plasma and platelet
ysate was also determined by ELISA (R&D Systems,
bingdon, United Kingdom), standardized by recombinant
uman P-selectin. The intra-assay coefficient of variation
or ELISA was 2.8% at 60 ng/ml, 3.8% at 6 ng/ml, and
.0% at 3 ng/ml (n  64). The inter-assay coefficient of
ariation for ELISA was 6.7% at 60 ng/ml, 8.5% at 5.5
g/ml, and 7.8% at 3.0 ng/ml (n  12). The lower limit of
ensitivity of the assay was 0.8 ng/ml.
Levels of pP-sel were measured by a lysate technique, as
reviously described in detail (20). Briefly, platelet-rich
lasma was obtained by centrifugation of venous blood at
00g for 10 min. From this, 108 platelets were pelleted by
entrifugation at 1,000g for 20 min, washed in phosphate-
uffered saline, and lysed by a small volume (250 l) of 0.1%
riton X-100 (Sigma, Poole, United Kingdom). The total
mount of P-selectin in an aliquot of this lysate is deter-
ined by ELISA and is reported as ng/cell after adjustment.
Platelet parameters—total platelet count, MPV, mean
latelet mass (MPM), and mean platelet granularity (MPG,
lso known as component)—were measured using flow
ytometry by an ADVIA 120 (Bayer, Newbury, Berks,
nited Kingdom). These indexes are obtained from histo-
rams of two-dimensional, light-scatter signals that are
onverted into volume and refractive index values; MPV
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July 21, 2004:415–22 Platelet and Soluble P-Selectin in Hypertensionfemtoliter [fl]) is directly measured, but both MPG (g/dl)
nd MPM (pg) are derived (17,21).
ower calculations. We based our power calculation on
ur previous reports of raised sP-sel in other hypertensive
atients from this trial (12), in atherosclerosis (7), and in
trial fibrillation (20). By hypothesizing an increase in sP-sel
n TOD, compared with patients free of TOD, of 20%
0.5 SD after log transformation), we needed at least 60
atients per group for two-tailed p  0.01 with a 1  beta
ower of 0.9 (22). The same power calculation was used for
he case-control aspect. The main post hoc analysis (i.e., on
spirin versus not on aspirin) is also powered for this
ifference.
tatistics. The Anderson-Darling test was applied to data
f continuous variables to define distribution. Results are
xpressed as the mean value  SD or as the median value
ith interquartile range for normally distributed data and
kewed data, respectively. Data between patients and con-
rols were analyzed by the unpaired t test or Mann-Whitney
test, as appropriate. Multivariate logistic regression anal-
ses were performed to seek relationships between categor-
cal data (e.g., on/off aspirin, on/off statin, with/without
OD) and the research indexes. Correlations were per-
ormed by Spearman’s correlation method. Differences be-
ween categorical data were sought using the chi-square test.
ll statistical calculations were performed on a microcom-
uter using a commercially available statistical package
Minitab release 12, Minitab Inc., State College, Pennsyl-
ania). A p value of 0.05 was considered statistically
ignificant.
ESULTS
s our recruitment numbers have exceeded our power
alculation (i.e., ability to determine, with high confidence,
difference of 20%/0.5 SD), we are confident of having
Table 1. Baseline Characteristics of Patients an
Health
(n
Age (yrs) 6
Males 41
SBP (mm Hg) 13
DBP (mm Hg) 80.
Smokers (% admitting)
Platelet indexes
Platelet count  106/ml 22
MPV (fl) 6.3
MPM (pg) 1.7
MPG (g/dl) 2
Beta-TG (IU/ml) 100
Soluble P-selectin (ng/ml) 77
Platelet P-selectin (106 ng/cell) 78.3
*Obtained from the unpaired t test (for age, blood pressure,
(beta-TG, soluble and platelet P-selectin), or the chi-square
or median value (interquartile range).
Beta-TG  beta-thromboglobulin; DBP  diastolic blo
platelet mass; MPV  mean platelet volume; SBP  systoliinimized type 1 and type 2 errors (22). sase-control aspect. The demographic, clinical, and
latelet parameters of the control and hypertensive subjects
re shown in Table 1. Of the hypertensive patients, 49%
ere taking a calcium channel blocker, 44% beta-blocker,
2% angiotensin-converting enzyme inhibitor, 37% alpha-
locker, 44% diuretic, and 9% angiotensin receptor blocker.
further 52% were taking aspirin and 33% a statin (all were
aking 10 mg atorvastatin, as per the ASCOT protocol),
nd 72 (36%) had diabetes. The hypertensive patients had a
ignificantly higher mean SBP, but not DBP, as compared
ith controls. Despite similar age, gender, and mean plate-
et counts, every platelet index was higher in the hyperten-
ive group compared with the control group, except MPG,
hich was lower.
nalyses within the hypertensive population. Of the 199
atients with hypertension, 125 (63%) had evidence of
OD (stroke in 25%, transient ischemic attack in 16%,
revious MI in 24%, angina in 20%, evidence of left
entricular hypertrophy in 11%, and mild renal failure in
0%). Patients with TOD had a significantly higher MPV
nd MPM but lower MPG. However, median levels of
lasma beta-TG were not significantly different, whereas
P-sel and pP-sel were significantly lower in the hyperten-
ive patients with TOD (Table 2).
Aspirin, an established antiplatelet agent, was being taken
egularly by 105 patients at a dose of 75 mg/day in a
tandardized manner when studied. We therefore analyzed
he data with respect to the use of this drug (Table 3).
nsurprisingly, patients taking aspirin were more likely to
ave cardiovascular disease and, thus, to be taking beta-
lockers, but there were fewer diabetics. The use of aspirin
as also associated with a higher MPM and MPV but lower
P-sel, pP-sel, and beta-TG values. There were no signifi-
ant differences in research indexes between patients who
ere taking a statin and those who were not (data not
ontrols
ntrols
9)
All Hypertensives
(n  199) p Value*
1 68  10 0.7
) 151 (76%) 0.3
0 147  22 0.001
80.1  11 0.9
12.5 0.001
9 239  65 0.2
.9 7.8  3.03 0.005
.17 1.9  0.21 0.001
.3 27.1  2.5 0.001
282) 307 (210–354) 0.001
110) 150 (106.8–213) 0.001
120) 99.6 (73.2–138.5) 0.004
et count, MPV, MPM, MPG), the Mann-Whitney U test
ales, smokers). Data are presented as the mean value  SD
essure; MPG  mean platelet granularity; MPM  mean
d pressure.d C
y Co
 5
8  1
(69%
0  1
5  9
0
7  4
6  0
6  0
9  2
(57–
(38–
(47–
platel
test (m
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Platelet and Soluble P-Selectin in Hypertension July 21, 2004:415–22orrelations. In the 59 healthy controls (i.e., in “normal”
hysiology), there was a strong positive correlation be-
ween MPM and MPV (i.e., large platelets have greater
ass), but a strong inverse relationship between MPV
nd MPG (i.e., large platelets have a lower concentration
f granules). There were no correlations with the platelet
ount. Levels of sP-sel significantly (but weakly) corre-
ated with pP-sel values (Fig. 1). Unsurprisingly, sP-sel
orrelated strongly with beta-TG, and the latter also
orrelated with pP-sel. Beta-thromboglobulin correlated
ith MPG, but neither pP-sel nor sP-sel did so.
Within the 199-strong hypertensive patient group (i.e., in
pathology”), the positive correlation between platelet mass
nd size was still present, albeit weaker, but the correlation
etween size and granularity disappeared. There were,
owever, no significant correlations between sP-sel and
P-sel in the hypertensive group as a whole, although, again
nsurprisingly, sP-sel correlated with beta-TG, but less
trongly than in the controls. Interestingly, pP-sel correlated
ith MPG.
In the 74 patients free of TOD, the only significant
orrelations were between sP-sel and beta-TG, MPG, and
PV, as well as between MPM and MPV.
Similarly, in the 125 patients with TOD, there was a
Table 2. Platelet Parameters According to the
HT Wi
(n
Age (yrs) 67
Males 58 (
SBP (mm Hg) 146
DBP (mm Hg) 81
Past medical history
IHD
CVA/TIA
DM 34 (
Drugs
Aspirin 12 (
Beta-blockers 25 (
Calcium antagonist 40 (
ACE inhibitors 29 (
Diuretics 35 (
A-II receptor antagonist 10 (
Smokers (% admitting)
Sokolow Lyon score on ECG 23
Cholesterol (mmol/l) 5.1
Platelet indexes
Platelet count (106/ml) 244
MPV (fl) 7.2
MPM (pg) 1.88
MPG (g/dl) 27.6
Soluble P-selectin (ng/ml) 160 (
Platelet P-selectin (106 ng/cell) 110 (
Beta-TG (IU/ml) 300 (
*Obtained by the unpaired t test (for age, blood pressure, plat
the Mann-Whitney U test (beta-TG, soluble and platelet
chi-square test (other categorical data). Data are presented a
ACE  angiotensin-converting enzyme; A-II  angioten
ECG  electrocardiogram; HT  hypertension; IHD  is
transient ischemic attack; TOD  target organ damage; othignificant correlation between sP-sel and beta-TG, and, in sddition, MPG correlated with pP-sel. However, the cor-
elations between MPG and MPV and between MPM and
PV were no longer significant, although a new correlation
etween MPG and MPM appeared. Principal correlations
re summarized in Table 4.
ultivariate analysis. Stepwise multiple regression analy-
is showed that among the hypertensive patients, the use of
spirin was an independent factor affecting (reducing) the
evels of sP-sel and pP-sel. Therefore, this seems to explain
he potential anomaly whereby patients with TOD have
ower levels of these platelet activation markers. No other
actors (including smoking and diabetes, both known to
nfluence sP-sel, or the use of drugs such as statins,
eta-blockers, or calcium channel blockers or nitrates)
ffected either of the P-selectin values.
ISCUSSION
growing mass of data implies that the platelet is impor-
ant in hypertension (23,24). For example, we, as well as
thers, have noted raised sP-sel in hypertension (12,13,25)
nd have also shown abnormalities in other indexes of
latelet physiology: increased pP-sel, MPV, and MPM, but
ower mean platelet (component) granularity (MPG), de-
nce or Absence of Target Organ Damage
TOD
)
HT With TOD
(n  125) p Value*
5 69  10 0.2
93 (74%) 0.5
148  24 0.7
80  12 0.9
59 (47%)
51 (41%)
38 (31%) 0.03
93 (62%) 0.001
64 (42%) 0.01
59 (39%) 0.3
52 (34%) 0.7
54 (36%) 0.5
) 9 (6%) 0.3
15.0 0.01
1 23 (18–30) 0.3
1 4.9  1.1 0.1
236  64 0.3
1 8.1  3.7 0.04
2 1.97  0.2 0.006
1 26.7  2.6 0.01
50) 130 (100–190) 0.001
0) 95 (60–130) 0.012
22) 310 (200–360) 0.19
unt, MPV, MPM, MPG, Sokolow Lyon score, cholesterol),
ctin, and other nonparametrically distributed data), or the
ean value  SD or median value (interquartile range).
CVA  cerebrovascular accident; DM  diabetes mellitus;
heart disease; PVD  peripheral vascular disease; TIA 
reviations as in Table 1.Prese
thout
 74
 9.
78%)
 20
 11
0
0
45%)
16%)
34%)
54%)
39%)
47%)
13.5%
4.0
 5.
 1.
 65
 1.
 0.
 2.
123–2
85–15
262–3
elet co
P-sele
s the m
sin II;
chemicpite similar platelet counts. Platelets activated by thrombin
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July 21, 2004:415–22 Platelet and Soluble P-Selectin in Hypertensionave lower densities and reduced MPG (21). It follows that
ow MPG may be consistent with (but does not conclusively
emonstrate) platelet activation. Indeed, patients with acute
I have lower MPG than those with unstable angina (17).
owever, as MPM and MPG are not derived directly
26,27), some degree of caution in interpretation is required,
s inter-relationships may be more mathematic than phys-
ologic. The inverse correlation between MPG (granularity)
nd MPV (volume) in the controls (i.e., in health) implies
hat large platelets have reduced granularity, and notably,
his relationship is not present in the entire patient cohort.
owever, the relationship reappears in the 74 patients free
f TOD, not in the 125 with TOD, implying the effect is
ependent not on hypertension but on TOD. Similarly, the
ositive relationship between mass and volume holds for all
Table 3. Analysis of Data Based on Utilization
Patients N
(n
Age (yrs) 69
Males 73
SBP (mm Hg) 147
DBP (mm Hg) 81
Smoking (% admitting)
Past medical history
IHD 3 (
CVA/TIA 17 (
DM 39 (
Drugs
Beta-blockers 31 (
Calcium antagonist 46 (
ACE inhibitors 32 (
Diuretics 49 (
A-II receptor antagonist 11 (
Platelet indexes
MPV (fl) 7.3 (
MPM (pg) 1.8
MPG (g/dl) 27.2
Soluble P-selectin (ng/ml) 160 (
Platelet P-selectin (106 ng/cell) 105 (
Beta-TG (IU/ml) 310 (
Data are presented as the mean value  SD, median value (
unpaired t test, Mann-Whitney U test, or the chi-square tes
Abbreviations as in Tables 1 and 2.
igure 1. Relationship between soluble P-selectin and platelet P-selectin
n normal control subjects. Spearman correlation coefficient, r  0.317, pm0.001.roups, except the patients with TOD, implying differing
latelet physiology in the latter. This is the reverse of the
ass-granularity correlation, present only in the patients
ith TOD. Finally, pP-sel correlated with granularity in the
ntire group of patients and in those with TOD alone, again
mplying an effect due to TOD and not simply to hyper-
ension.
Many investigators have shown platelet activation in
ypertension, as reflected by increases in plasma markers
uch as beta-TG (23) and platelet factor-4 (24,28,29), and
ur present data support this work. Increased MPV has
een described (30), although not all studies confirm this
31). Raised MPV is also a risk factor for MI (32) and, in
ddition, is a marker of platelet activation (33–35). How-
ver, the link between other aspects of platelet physiology in
ypertension and the presence of TOD has not been
reviously documented (i.e., raised MPV and MPM and
ower MPG). Flow cytometry is a popular method for
ssessing platelet activation (25,36), but detects only the
-selectin that is expressed on the cell surface, not the
-selectin present as part of the granule membrane and not
yet) expressed on the cell surface. Our method (20) of
ysing platelets with a detergent and then performing
LISA on the lysate bypasses this potential problem.
The reason(s) for increased pP-sel in hypertension are
nclear but may reflect changes in megakaryocyte processing
nd/or thrombopoietin in response to changes in vascular
unction. P-selectin per platelet correlated with MPG,
uggesting to us that the more granular platelets contain
spirin
Aspirin
)
Patients on Aspirin
(n  105) p Value
68  9 0.7
77 (73) 0.5
147  24 0.9
79  10 0.2
16.7 0.131
55 (52%) 0.001
34 (32%) 0.03
33 (32%) 0.001
58 (55%) 0.003
53 (50%) 0.8
49 (46%) 0.08
40 (30%) 0.04
8 (7%) 0.3
.9) 7.8 (6.9–8.4) 0.007
19 1.9  0.2 0.01
5 27.1  2.5 0.5
20) 130 (100–195) 0.01
0) 95 (60–125) 0.01
40) 300 (200–360) 0.03
artile range) or number (%) of subjects. Comparisons using
ppropriate.of A
ot on
 93
 9
(78)
 21
 13
7.5
3%)
18%)
42%)
33%)
49%)
34%)
53%)
12%)
6.7–7
 0.
 2.
120–2
85–15
220–3
interqu
t, as aore P-selectin. However, the correlation in the subgroup
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Platelet and Soluble P-Selectin in Hypertension July 21, 2004:415–22f hypertensive patients with TOD was slightly stronger,
uggesting the effect is more likely to be related to TOD and
ess so to hypertension. In the controls, sP-sel correlated
ith beta-TG, sP-sel correlated with pP-sel, and pP-sel
orrelated with beta-TG. However, only the beta-TG/sP-
el correlation remained in the patients, regardless of TOD.
his further emphasizes the differences between beta-TG (a
oluble component of the matrix of the alpha granule) and
-selectin (a component of granule membranes). One
ossible explanation for this is that platelets in the patients
ave reduced granularity simply because they are larger than
ormal platelets. Nonetheless, this alone does not explain
aised pP-sel. We therefore suggest that granules in pa-
ients’ platelets have more P-selectin than the granules from
ontrols—a hypothesis that explains raised sP-sel and
eta-TG (both resulting from degranulation) and raised
P-sel (an index independent of mass and volume), as well
s the positive correlation between pP-sel and granularity,
trongest in the patients with TOD. Platelets are known to
e affected by smoking (37–39). However, it is unlikely that
he presence of smokers in our hypertensive group ac-
ounted for the differences in the two groups, as the
umbers are small; indeed, there was no significant differ-
nce in the research indexes between the smokers and
onsmokers within the hypertensive group in the present
tudy (data not shown).
Studies with aspirin have shown variable results on
-selectin (40–43). More recently, aspirin alone or aspirin
lus clopidogrel failed to influence sP-sel in patients with
cute coronary syndromes (44), and, in health, sP-sel seems
o be uninfluenced by aspirin (45,46). We add to this debate
y showing that the use of aspirin was associated with lower
P-sel and pP-sel and higher MPV and MPM, but no
ifference in MPG, despite similar blood pressure (Table 3).
lthough these differences may be causal, we acknowledge
hat an intervention study in these patients would provide
etter data than the present cross-sectional design.
Table 4. Principal Correlations
Control
Subjects
A
W
Platelet volume and 0.669
granularity 0.001
Platelet volume and 0.699
mass 0.001
Platelet mass and 0.053
granularity 0.760
Platelet P-selectin and 0.048
granularity 0.785
Soluble P-selectin and 0.317
platelet P-selectin 0.001
Beta-thromboglobulin 0.483
and soluble P-selectin 0.001
Beta-thromboglobulin 0.301
and platelet P-selectin 0.029
Data are presented as the Spearman correlation coefficient a
HT  hypertension; TOD  target organ damage.Nonetheless, our data do imply that the cyclooxygenase (athway influences the metabolic and/or signalling aspects
f P-selectin, maybe in the megakaryocyte (47). Aspirin use
as also associated with greater use of beta-blockers, and we
cknowledge the possible influence of this class of drug on
latelets (48). However, we cannot propose a clear mecha-
ism by which aspirin use leads to larger and heavier
latelets at the same time as reduced sP-sel, pP-sel, and
eta-TG, which is compatible with our other explanations.
herefore, differences may be spurious or simply due to the
reater degree of cardiovascular disease and its risk factors in
hose patients taking aspirin.
The findings of this study have some important implica-
ions for the minimization of TOD and cardiovascular
vents in hypertensive patients. Despite the modulating use
f aspirin and other therapies (although directed at blood
ressure), patients with TOD still have abnormal platelet
ndexes as compared with healthy age- and gender-matched
ontrols. Notably, P-selectin expression on platelets deter-
ines the size and stability of platelet aggregates (49), and
in an animal model) a procoagulant state results from high
evels of sP-sel in blood (50). These lend support to the
rgument that all high-risk hypertensive patients should be
reated with antiplatelet agents such as aspirin and/or
lopidogrel. Indeed, the Hypertension Optimal Treatment
HOT) study has shown that adding an antiplatelet agent to
revent platelet activation translates into clinical benefits
51).
The present analysis primarily assesses the relation of our
esearch indexes to TOD, but is limited by its cross-
ectional comparison. We are well powered to show that
atients with hypertension have evidence of abnormalities in
latelets, as reflected by a higher level of pP-sel, and that
ost of this can be explained by additional TOD. The low
latelet granularity in hypertension, with or without TOD,
ay represent those activated cells that have degranulated
nd are still circulating (52) (having shed their sP-sel, which
hen appears in the plasma) or may alternatively simply
ients
HT
HT Patients
With No TOD
HT Patients
With TOD
72 0.597 0.027
16 0.001 0.772
60 0.770 0.178
01 0.001 0.051
06 0.038 0.194
41 0.746 0.033
28 0.169 0.234
01 0.150 0.01
83 0.159 0.109
45 0.176 0.227
23 0.300 0.220
02 0.01 0.014
46 0.126 0.017
18 0.286 0.852
alue.ll Pat
ith
0.0
0.3
0.2
0.0
0.1
0.1
0.2
0.0
0.0
0.2
0.2
0.0
0.0
0.5
nd p vmathematically) reflect increased platelet volume and mass.
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ontinue to circulate (52), one would expect to see greater
evels of plasma sP-sel in patients with TOD, in contrast to
he present study. Furthermore, because of the case-control
ethodology used, we cannot be certain of causality (i.e.,
ause or effect of the disease), nor that the medications are
ot responsible for a component of the changes in our
esearch indexes.
onclusions. Patients with hypertension have evidence of
hanges in platelet physiology, as reflected by a higher level
f pP-sel. Patients with TOD also have larger platelets, with
reater mass, and the use of aspirin did lower pP-sel and
P-sel levels. These changes may have implications for the
athophysiology of cardiovascular and cerebrovascular dis-
ase in hypertension.
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